In sports, doping abuse done by athletes has been done since the 18th century. Many of the drugs used for doping and its chemical properties vary. Based on a list issued by the World Anti Doping Agency, one of the doping categories is diuretic. Then the most appropriate testing method is needed to seperation furosemide and indapamide. This study aims to see the development and validation of the separation furosemide and indapamide as doping compounds with High Performance Liquid using the Zic - HILIC column. This study used High Performance Liquid Chromatography of Shidmazu LC 20 AD brand with iso-fed pump and SPD 20A UV-Vis detector. The column used is Zic - HILIC (150 x 4.6 mm; 5 μm). This research is carried out on the optimization of conditions including mobile phase velocity, mobile phase pH, buffer of mobile phase, and buffer concentration. Selection of selected conditions see the price of R> 1.5 and N >>> or HETP << 1.5 and the N price is the greatest. The method was than validated forSelectivity, linearity,accuracy, precision, limits ofdetection and limits ofquantification. The calibration curve of furosemide and indapamide were linear with a regression coefficient R > 0.999.
{"title":"DEVELOPMENT AND VALIDATION ZIC HILIC COULOMN FOR SIMULTANEOUS DETERMINATION OF FUROSEMIDE AND INDAPAMIDE AS DOPING","authors":"Iswandi Iswandi","doi":"10.37013/jf.v1i1.64","DOIUrl":"https://doi.org/10.37013/jf.v1i1.64","url":null,"abstract":"In sports, doping abuse done by athletes has been done since the 18th century. Many of the drugs used for doping and its chemical properties vary. Based on a list issued by the World Anti Doping Agency, one of the doping categories is diuretic. Then the most appropriate testing method is needed to seperation furosemide and indapamide. This study aims to see the development and validation of the separation furosemide and indapamide as doping compounds with High Performance Liquid using the Zic - HILIC column. This study used High Performance Liquid Chromatography of Shidmazu LC 20 AD brand with iso-fed pump and SPD 20A UV-Vis detector. The column used is Zic - HILIC (150 x 4.6 mm; 5 μm). This research is carried out on the optimization of conditions including mobile phase velocity, mobile phase pH, buffer of mobile phase, and buffer concentration. Selection of selected conditions see the price of R> 1.5 and N >>> or HETP <<<Optimized wavelength results 276 nm. The separation conditions of the furosemide and indapamide mixtures by HPLC using Zic-HILIC columns (150 x 4.6 mm, 5 μm) are Acetonitrile: Ammonium Acetate buffer (5 mM, pH 5) (95: 5) with a velocity of 0.5 ml / minute. The selected condition gives the given resolution value> 1.5 and the N price is the greatest. The method was than validated forSelectivity, linearity,accuracy, precision, limits ofdetection and limits ofquantification. The calibration curve of furosemide and indapamide were linear with a regression coefficient R > 0.999.","PeriodicalId":17954,"journal":{"name":"Jurnal Farmasi (Journal of Pharmacy)","volume":"72 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85925926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Fisetin (3,3,4,7-tetrahydroxyflavone) is a natural antioxidanthaspoor solubility leads to poorbioavailability and limits its development. Fisetinnanocrystals were produced by nanoprecipitation technique and transformed into dry powder by lyophilisation. Objective: The aim of the study is to investigate the kinetic solubility of fisetinafter produced into nanocrystals. Methods: Fisetin nanocrystalswere prepared by nanoprecipitationwith different proportion of stabilizers and transformed into dry powder by lyophilization. In a period of 1 week, the kinetic solubility was determined using a shaker water bath at 37OC. Result: Showed fisetin nanocrystals were almost completely dissolved within 15 min in water and buffer pH 1,2. In contras, only 55% of fisetin raw material at the same condition. Conlusions: Lyophilizedfisetinnanocrystals could be re-dispersed completely in water, buffer pH 1,2 and the kinetic solubility in water increased to 420 ηg/ml.
{"title":"KINETIC SOLUBILITY OF FISETIN NANOCRYSTAL","authors":"M. Dzakwan","doi":"10.37013/jf.v1i1.56","DOIUrl":"https://doi.org/10.37013/jf.v1i1.56","url":null,"abstract":"Background: Fisetin (3,3,4,7-tetrahydroxyflavone) is a natural antioxidanthaspoor solubility leads to poorbioavailability and limits its development. Fisetinnanocrystals were produced by nanoprecipitation technique and transformed into dry powder by lyophilisation. Objective: The aim of the study is to investigate the kinetic solubility of fisetinafter produced into nanocrystals. Methods: Fisetin nanocrystalswere prepared by nanoprecipitationwith different proportion of stabilizers and transformed into dry powder by lyophilization. In a period of 1 week, the kinetic solubility was determined using a shaker water bath at 37OC. Result: Showed fisetin nanocrystals were almost completely dissolved within 15 min in water and buffer pH 1,2. In contras, only 55% of fisetin raw material at the same condition. Conlusions: Lyophilizedfisetinnanocrystals could be re-dispersed completely in water, buffer pH 1,2 and the kinetic solubility in water increased to 420 ηg/ml.","PeriodicalId":17954,"journal":{"name":"Jurnal Farmasi (Journal of Pharmacy)","volume":"138 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77479036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AbstractKanker adalah pertumbuhan sel pada berbagai jaingan dalam tubuh, sebagian besar tumbuh pada jaringan sel induknya. Setiap tahun dijumpai hamper 6 juta penderita baru yang diketahui mengidap kanker dan lebih dari 4 juta diantaranya meninggal. Sampai saat ini pengobatan kanker dilakukan dengan 3(tiga) cara yaiu radiasi, pembedahan dan pengobatan menggunakan ahan kimia anti-kanker. Pengobatan seperti ini sering memberikan efek samping terhadap pasien. Penelitian ini ertujuan untuk melakukan serangkaian uji pra-klinis untuk menentukanmenentukan dosis yang optimal ekstraks Myrmecodia Pendans yang digunakan sebagai obat kanker Paru. Tujuan khusus dalam penelitian ini adalah melakukan ekstraksi Myrmecodia Pendans untuk menghasilkan obat alternatif kanker. Manfaat penelitian ini adalah penggunaan umbi Myrmecodia Pendans sebagai obat herbal untuk terapi kanker. Uji ini dilakukan dengan menggunakan tikus putih yang diinduksi dengan DMBA (Dymethyl [a]anthracene) dengan dosis 20mg/kgBB sebanyak 10 kali selama 5 Minggu sebagai model. Terapi dilakukan dengan menginduksi ekstraks Myrmecodia Pendans dengan dosis 250mg/kgBB, 500mg/kgBB dan 750mg/kgBB. Berdasarkan uji Histopatologi dapat dinyatakan bahwa sel paru yang mengalami kerusakan akibat pemberian DMBA dapat diperbaiki dengan ekstrak Myrmecodia Pendans dengan dosis 750mg/kgBB.
{"title":"Uji Praklinis Anti-Kanker Myrmecodia Pendans Pada Tikus Putih yang Diinduksi 7,12 –dymethylbenz[α]anthracene (DMBA)","authors":"S. Suharyanto, Winarto Haryadi","doi":"10.37013/JF.V7I1.47","DOIUrl":"https://doi.org/10.37013/JF.V7I1.47","url":null,"abstract":"AbstractKanker adalah pertumbuhan sel pada berbagai jaingan dalam tubuh, sebagian besar tumbuh pada jaringan sel induknya. Setiap tahun dijumpai hamper 6 juta penderita baru yang diketahui mengidap kanker dan lebih dari 4 juta diantaranya meninggal. Sampai saat ini pengobatan kanker dilakukan dengan 3(tiga) cara yaiu radiasi, pembedahan dan pengobatan menggunakan ahan kimia anti-kanker. Pengobatan seperti ini sering memberikan efek samping terhadap pasien. Penelitian ini ertujuan untuk melakukan serangkaian uji pra-klinis untuk menentukanmenentukan dosis yang optimal ekstraks Myrmecodia Pendans yang digunakan sebagai obat kanker Paru. Tujuan khusus dalam penelitian ini adalah melakukan ekstraksi Myrmecodia Pendans untuk menghasilkan obat alternatif kanker. Manfaat penelitian ini adalah penggunaan umbi Myrmecodia Pendans sebagai obat herbal untuk terapi kanker. Uji ini dilakukan dengan menggunakan tikus putih yang diinduksi dengan DMBA (Dymethyl [a]anthracene) dengan dosis 20mg/kgBB sebanyak 10 kali selama 5 Minggu sebagai model. Terapi dilakukan dengan menginduksi ekstraks Myrmecodia Pendans dengan dosis 250mg/kgBB, 500mg/kgBB dan 750mg/kgBB. Berdasarkan uji Histopatologi dapat dinyatakan bahwa sel paru yang mengalami kerusakan akibat pemberian DMBA dapat diperbaiki dengan ekstrak Myrmecodia Pendans dengan dosis 750mg/kgBB.","PeriodicalId":17954,"journal":{"name":"Jurnal Farmasi (Journal of Pharmacy)","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90369476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Download Full Issue Volume 10, No. 1, Maret 2021","authors":"Full Issue","doi":"10.37013/jf.v10i1.120","DOIUrl":"https://doi.org/10.37013/jf.v10i1.120","url":null,"abstract":"Download Full Issue Volume 10, No. 1, Maret 2021","PeriodicalId":17954,"journal":{"name":"Jurnal Farmasi (Journal of Pharmacy)","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74489003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：